Moderna Inc (OQ:MRNA)

Business Focus: Biotechnology & Medical Research

Dec 03, 2020 05:07 pm ET
Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided an update on the clinical development and production of mRNA-1273, its vaccine candidate against COVID-19.
Dec 02, 2020 08:31 am ET
Thinking about trading options or stock in Intel Corp, Moderna, General Electric, American Airlines, or Exxon Mobil?
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INTC, MRNA, GE, AAL, and XOM....
Dec 01, 2020 07:30 am ET
Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT....
Nov 30, 2020 07:30 am ET
Thinking about buying stock in Moderna, Aurora Cannabis, China Automotive Systems, GameStop, or Sunesis Pharmaceuticals?
NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, ACB, CAAS, GME, and SNSS....
Nov 30, 2020 06:59 am ET
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analys
Nov 29, 2020 08:37 am ET
Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the UK government for an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to the United Kingd
Nov 27, 2020 01:01 pm ET
Moderna to Present at Upcoming Investor Conferences in December 2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences:
Nov 27, 2020 08:31 am ET
Thinking about trading options or stock in Novavax, Tesla, AstraZeneca, Apple, or Moderna?
NEW YORK, Nov. 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVAX, TSLA, AZN, AAPL, and MRNA....
Nov 25, 2020 08:31 am ET
Thinking about buying stock in Altimmune, General Electric, Moderna, Delta Air Lines, or Norwegian Cruise Line?
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALT, GE, MRNA, DAL, and NCLH....
Nov 25, 2020 06:49 am ET
Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, as part of th
Nov 23, 2020 07:30 am ET
Thinking about buying stock in HTG Molecular Diagnostics, Moderna, FuelCell Energy, BioNTech, or Blink Charging?
NEW YORK, Nov. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTGM, MRNA, FCEL, BNTX, and BLNK....
Nov 19, 2020 08:31 am ET
Thinking about trading options or stock in JOYY Inc, Moderna, Fiserv, L Brands, or Nikola Corp?
NEW YORK, Nov. 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for YY, MRNA, FISV, LB, and NKLA....
Nov 18, 2020 07:30 am ET
Thinking about buying stock in Pfizer, Moderna, Micro Focus, Riot Blockchain, or PG&E Corp?
NEW YORK, Nov. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, MFGP, RIOT, and PCG....
Nov 17, 2020 09:18 am ET
European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Company’s vaccine candidate agains
Nov 17, 2020 09:11 am ET
Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the government of the United Kingdom to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if it is approved
Nov 16, 2020 07:30 am ET
Thinking about buying stock in Pfizer, Moderna, Inovio Pharmaceuticals, AMC Entertainment, or HighPoint Resources?
NEW YORK, Nov. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, INO, AMC, and HPR....
Nov 16, 2020 06:56 am ET
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has inf
Nov 16, 2020 06:52 am ET
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remains stable at 2° to 8°C (36° to 46°F), the temperature of a standard home or medical r
Nov 13, 2020 07:18 am ET
Swissmedic Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Swissmedic has started a rolling review of mRNA-1273, the Company’s vaccine candidate against COVID-19. This announcement follows
Nov 12, 2020 07:30 am ET
Thinking about buying stock in Moderna, ACCO Brands, Top Ships, JD.Com, or Xpeng?
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, ACCO, TOPS, JD, and XPEV....
Nov 11, 2020 04:01 pm ET
Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed case accrual for the first interim analysis of the Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate.
Nov 11, 2020 09:55 am ET
Should you invest in American Airlines, Microsoft, Plug Power, Sorrento Therapeutics, or Moderna?
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, MSFT, PLUG, SRNE, and MRNA....
Nov 11, 2020 07:09 am ET
Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today shared interim data from the expansion cohort of its ongoing Phase 1 study of the Company’s mRNA personalized cancer vaccine (PCV) mRNA-4157 in combination with Merc
Nov 02, 2020 08:33 am ET
Moderna to Present at Upcoming Investor Conferences in November 2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:
Oct 30, 2020 09:29 am ET
Moderna Named Top Employer by Science for Sixth Consecutive Year
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced it has been named one of the global biopharmaceutical industry’s top employers in Science and Science Careers’
Oct 29, 2020 09:31 am ET
Thinking about trading options or stock in Moderna, Nio, Overstock.com, Marvell Technology, or Walt Disney?
NEW YORK, Oct. 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, NIO, OSTK, MRVL, and DIS....
Oct 29, 2020 07:00 am ET
Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results and provided business updates for the third quarter of 2020 and highlighted pipeline progress.
Oct 29, 2020 02:00 am ET
Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co., Ltd (NYSE: TAK) have agreed to purchase and distribute 50 mi
Oct 27, 2020 09:00 am ET
UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna has initiated the rolling submission of mRNA-1273 data for rolling review, in consideration of a potential authorization by the MHRA, provided the vaccine candidate meets the MHRA’s rigorous standards of safety, effectiveness, and quality standards. This rolling review process allows the MHRA to begin its independent assessment using the information submitted by Moderna and accept new evidence as it becomes available until the application is deemed complete. This process can reduce time to authorization while maintaining usual high standards of safety, efficacy, and quality.
Oct 26, 2020 09:31 am ET
Thinking about trading options or stock in Apple, Boeing, Moderna, ServiceNow, or Zoom Video?
NEW YORK, Oct. 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, BA, MRNA, NOW, and ZM....
Oct 26, 2020 07:00 am ET
Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoi
Oct 23, 2020 09:31 am ET
Thinking about trading options or stock in Moderna, General Electric, Walt Disney, F5 Networks, or Capital One?
NEW YORK, Oct. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, GE, DIS, FFIV, and COF....
Oct 22, 2020 09:47 am ET
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, its vaccine candidate against COVID-19, being conducted in
Oct 20, 2020 09:31 am ET
Thinking about trading options or stock in Moderna, Procter & Gamble, Microsoft, AT&T, or NVIDIA?
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, PG, MSFT, T, and NVDA....
Oct 19, 2020 10:00 am ET
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual)
Join us as we discuss today’s pressing healthcare issues.
Oct 15, 2020 04:15 pm ET
Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.
Oct 14, 2020 08:00 am ET
Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has received written confirmation from the European Medicine Agency (EMA) that mRNA-1273, the Company’s vaccine candidate against COVID-19, is eligi
Oct 13, 2020 11:04 am ET
Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initiation follows
Oct 08, 2020 06:50 am ET
DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an agreement for a commitment of up to $56 million from the Defense Advanced Research Projects Agency (DARPA) to fund development of a
Oct 08, 2020 06:45 am ET
Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, known as MSD outside the United States and Canada,
Sep 29, 2020 06:17 pm ET
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in
Sep 28, 2020 09:00 am ET
Moderna to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
A live webcast will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.
Sep 22, 2020 12:22 pm ET
Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Canadian Government has increased its confirmed order commitment to 20 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273.
Sep 17, 2020 06:59 am ET
Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced progress across its portfolio of pipeline assets being presented at the Company’s annual R&D Day today.
Sep 16, 2020 04:30 pm ET
Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing
Moderna, Inc. (Nasdaq:MRNA) and Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) announced today a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles (LNPs) and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF). The three-year research collaboration initially will focus on the discovery and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs, enabling functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to be p
Sep 16, 2020 04:01 pm ET
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), today announced a collaboration aimed at the discovery and development of mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH), a rare disease with an incidence of 2-5 per million adults1. PAH is a progressive disorder characterized by high blood pressure in the arteries of the lungs w
Sep 16, 2020 05:00 am ET
Moderna Announces First Commercial Organization Outside North America in Switzerland
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the appointment of Dan Staner as Vice President and General Manager, Switzerland, effective today. Switzerland is the first country outside of North America to host a Moderna regional hub and commercial organization.
Sep 10, 2020 08:00 am ET
Moderna Names Michael Mullette as Managing Director of New Canadian Subsidiary
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the appointment of Michael Mullette as Managing Director, Canada effective immediately.
Sep 09, 2020 08:15 am ET
Moderna to Present at Upcoming Investor Conferences in September 2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences:
Sep 08, 2020 06:30 am ET
Biopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech SE (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA),...
Sep 08, 2020 06:30 am ET
Biopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.
Sep 08, 2020 06:30 am ET
Biopharma Leaders Unite To Stand With Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.
Sep 03, 2020 08:00 am ET
Moderna to Host Virtual R&D Day on September 17, 2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its fourth annual virtual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 17.
Aug 28, 2020 06:19 am ET
Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company is engaged in discussions with the Ministry of Health, Labour and Welfare of Japan (MHLW) to potentially purchase 40 million or more doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support Japan’s aim of providing vaccines to the public as soon as possible. Under the terms of this arrangement, the vaccine would be supplied by Moderna, Inc. and distributed in Japa
Aug 26, 2020 08:53 am ET
Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced it is presenting at the Centers for Disease Control and Prevention’s Advisory Committee on Immunizatio
Aug 24, 2020 09:18 am ET
Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Company has concluded advanced exploratory talks with the European Commission to supply 80 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, as part of the European Commission’s goal to secure early access to safe and effective COVID-19 vaccines for Europe.
Aug 11, 2020 05:49 pm ET
Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people.
Aug 10, 2020 04:05 pm ET
John Lepore Joins Moderna as Senior Vice President, Government Engagement
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Lepore has joined Moderna as Senior Vice President, Government Engagement effective Monday, August 10, 2020. He will report to Chief Executive Officer, Stéphane Bancel.
Aug 06, 2020 09:31 am ET
Thinking about trading options or stock in Moderna Inc, Teladoc Health, Ford Motor, American Airlines, or Microsoft Corp?
NEW YORK, Aug. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, TDOC, F, AAL, and MSFT....
Aug 05, 2020 07:00 am ET
Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results and provided business updates for the second quarter of 2020 and highlighted pipeline progress.
Jul 30, 2020 05:04 pm ET
Moderna Announces Resignation of Dr. Elizabeth Nabel From Board of Directors
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the resignation of Elizabeth (Betsy) Nabel, M.D., from Moderna’s Board of Directors effective today, July 30. Dr. Nabel is President of Brigham and Women’s Hospital, which is participating as one of 89 clinical trial sites in the Phase 3 trial of mRNA-1273, Moderna’s vaccine candidate against COVID-19.
Jul 30, 2020 09:31 am ET
Thinking about buying stock in MobileIron Inc, Waitr Holdings, Electrameccanica Vehicles, Boeing, or Moderna Inc?
NEW YORK, July 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MOBL, WTRH, SOLO, BA, and MRNA....
Jul 28, 2020 03:23 pm ET
Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published in
Jul 28, 2020 10:45 am ET
Thinking about buying stock in Moderna, Ocugen Inc, Advanced Micro Devices, iBio Inc, or Taiwan Semiconductor?
NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, OCGN, AMD, IBIO, and TSM....
Jul 27, 2020 09:31 am ET
Thinking about trading options or stock in Moderna, Netflix, American Airlines, General Electric, or Ford?
NEW YORK, July 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, NFLX, AAL, GE, and F....
Jul 27, 2020 06:52 am ET
Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants. The Phase 3 study, called the COVE (Coronavirus Efficacy) study, is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development A
Jul 26, 2020 10:22 am ET
Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against COVID-19.
Jul 24, 2020 03:53 pm ET
Statement from Moderna on Patent Trial and Appeal Board (PTAB) Ruling
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today released a statement on the July 23rd U.S. Patent Trial and Appeal Board (PTAB) ruling:
Jul 22, 2020 08:00 am ET
Moderna to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
Moderna, Inc., (Nasdaq:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 5, 2020 to report its second quarter 2020 financial results and provide a corporate update.
Jul 20, 2020 10:35 am ET
Thinking about buying stock in Denbury Resources, AstraZeneca, Just Energy Group, Sorrento Therapeutics, or Moderna?
NEW YORK, July 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DNR, AZN, JE, SRNE, and MRNA....
Jul 17, 2020 09:31 am ET
Thinking about trading options or stock in Moderna, Penn National Gaming, Tesla, United Airlines, or Costco Wholesale?
NEW YORK, July 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, PENN, TSLA, UAL, and COST....
Jul 15, 2020 09:31 am ET
Thinking about trading stock or options in Moderna Inc, Vaxart Inc, MGM Resorts, First Solar, or UnitedHealth Group?
NEW YORK, July 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, VXRT, MGM, FSLR, and UNH....
Jul 14, 2020 05:14 pm ET
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in
Jul 14, 2020 09:31 am ET
Thinking about trading options or stock in Overstock.com, Moderna, Alibaba, Boeing, or Ford?
NEW YORK, July 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSTK, MRNA, BABA, BA, and F....
Jul 14, 2020 09:06 am ET
Moderna to Join the NASDAQ-100 Index Beginning July 20, 2020
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, announced that it will become a component of the NASDAQ-100 Index® (Nasdaq: NDX
Jul 13, 2020 10:33 am ET
Moderna, Inc. to Join the NASDAQ-100 Index Beginning July 20, 2020
Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior...
Jul 09, 2020 08:00 am ET
Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA vaccine candidate against COVID-19 (mRNA-1273) at ROVI’s facility in Madrid, Spa
Jul 08, 2020 09:44 am ET
Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against COVID-19. mRNA-1273 is Moderna’s second mRNA vaccine for an infectious disease to complete enrollment of a Phase 2 study, following the Company’s
Jul 07, 2020 08:00 am ET
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
CAMBRIDGE, Mass., July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source. ...
Jul 03, 2020 06:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Jul 01, 2020 08:00 am ET
Elizabeth Tallett Joins Moderna’s Board of Directors
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Elizabeth Tallett has joined its Board of Directors. Ms. Tallett was also appointed to serve on the Audit Committee of the Board. With the appointment of Ms. Tallett, Dr. François Nader is stepping down from the Audit Committee.
Jun 25, 2020 07:30 am ET
Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloom
Jun 25, 2020 07:30 am ET
Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloom
Jun 22, 2020 07:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Jun 16, 2020 03:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Pomerantz LLP is investigating claims on behalf of investors of  Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Jun 16, 2020 08:00 am ET
Moderna to Present at BMO 2020 Prescriptions for Success Healthcare Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stéphane Bancel, Chief Executive Officer, will participate virtually in the BMO 2020 Prescriptions for Success Healthcare Conference on June 23rd at 3:00 p.m. ET.
Jun 15, 2020 04:34 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Moderna, Inc. (MRNA) Investors of Ongoing Investigation into Possible Securities Fraud and Insider Trading, Encourages Investors with Significant Losse
Hagens Berman urges investors in Moderna, Inc. (NASDAQ: MRNA) to submit their losses now to learn if they qualify to recover their investment losses. Relevant Holding Period: Before June 1, 2020Visit: www.hbsslaw.com/investor-fraud/MRNA...
Jun 15, 2020 09:31 am ET
Thinking about trading options or stock in iRobot, Moderna, Advanced Micro Devices, Wells Fargo, or Apple?
NEW YORK, June 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IRBT, MRNA, AMD, WFC, and AAPL....
Jun 15, 2020 08:00 am ET
Ray Jordan Joins Moderna as Chief Corporate Affairs Officer
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Ray Jordan has joined Moderna as Chief Corporate Affairs Officer, effective Monday, June 15, 2020. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel.
Jun 12, 2020 10:50 pm ET
MODERNA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA).  Such investors are advised to contact...
Jun 12, 2020 10:55 am ET
Thinking about buying stock in Tesla, Oasis Petroleum, Moderna, Callon Petroleum, or Nio Inc?
NEW YORK, June 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, OAS, MRNA, CPE, and NIO....
Jun 11, 2020 07:57 am ET
Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19
Moderna has finalized the Phase 3 study protocol based on feedback from the U.S. Food and Drug Administration (FDA). The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the U.S. and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The trial’s primary endpoint will be the prevention of symptomatic COVID-19 disease; key secondary endpoints include prevention of severe COVID-19 disease (as defined by the need for hospita
Jun 08, 2020 05:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Jun 05, 2020 10:50 pm ET
MODERNA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA).  Such investors are advised to contact...
Jun 04, 2020 09:31 am ET
Thinking about trading options or stock in Air Transport Services, AAR Corp, United Airlines, Eldorado Resorts, or Moderna?
NEW YORK, June 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATSG, AIR, UAL, ERI, and MRNA....
Jun 04, 2020 08:00 am ET
David Meline Joins Moderna as Chief Financial Officer
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that David Meline has joined Moderna as Chief Financial Officer, effective Monday, June 8, 2020. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel.
Jun 03, 2020 04:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Pomerantz LLP is investigating claims on behalf of investors of  Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Jun 02, 2020 07:30 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Announces Investigation into Moderna, Inc. (MRNA) for Possible Securities Fraud and Insider Trading, Encourages Investors with Significant Losses to Contact Fi
Hagens Berman urges investors in Moderna, Inc. (NASDAQ: MRNA) to submit their losses now to learn if they qualify to recover their investment losses.  Relevant Holding Period: Before June 1, 2020Visit: www.hbsslaw.com/investor-fraud/MRNA...
Jun 02, 2020 02:54 pm ET
MRNA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Moderna, Inc. Investigation and Encourages Investors to Contact the Firm
NEW YORK, June 2, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mrna.             ...
Jun 02, 2020 07:30 am ET
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new research to be highlighted at the Company’s third annual Science Day, held virtually this year. The program is designed to provide insight into the continued diverse efforts underway at Moderna and with collaborators to better understand how to use mRNA as a medicine, and underscores the Company’s continued commitment to basic science and innovation.
Jun 01, 2020 10:50 pm ET
MODERNA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact...
Jun 01, 2020 10:39 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Possible Securities Fraud and Insider Trading, Encourages Moderna, Inc. (MRNA) Investors with Significant Losses to Contact Firm
SAN FRANCISCO, June 1, 2020 /PRNewswire/ -- Hagens Berman urges investors in Moderna, Inc. (NASDAQ: MRNA) to submit their losses now to learn if they qualify to recover their investment losses.  ...
May 29, 2020 04:52 pm ET
Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first participants in each age cohort have been dosed in the Company’s
May 28, 2020 08:00 am ET
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
CAMBRIDGE, Mass., May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity. ...
May 28, 2020 01:30 am ET
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2
LUXEMBOURG, May 28, 2020 /PRNewswire/ -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agreement with Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. The extension enables CordenPharma to manufacture large-scale volumes of Moderna's lipid excipients to be used in th...
May 28, 2020 01:30 am ET
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2
LUXEMBOURG, May 28, 2020 /CNW/ -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agreement with Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. The extension enables CordenPharma to manufacture large-scale volumes of Moderna's lipid excipients to be used in the manuf...
May 27, 2020 10:50 pm ET
MODERNA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA).  Such investors are advised to contact...
May 27, 2020 02:26 pm ET
Moderna, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Moderna, Inc. ("Moderna") (NASDAQ: MRNA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact...
May 27, 2020 10:00 am ET
The Law Offices of Frank R. Cruz Continues Its Investigation on Behalf of Moderna, Inc. Investors (MRNA)
The Law Offices of Frank R. Cruz continues its investigation on behalf of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a...
May 27, 2020 09:56 am ET
Shareholder Investigation: The Law Firm of Barbuto & Johansson, P.A. Investigates Moderna, Inc. (NasdaqGS: MRNA) After Vaccine Experts Lodge Criticism
Barbuto & Johansson, P.A. (“BARJO”) and Of Counsel, Neil Rothstein, Esq. (with over 30 years of Securities Class Action experience, including cases against ENRON and HALLIBURTON) advises that it has commenced an investigation into Moderna, Inc....
May 27, 2020 09:31 am ET
Thinking about trading stocks or options in Walt Disney, MGM Resorts, Alaska Air Group, Moderna, or Morgan Stanley?
NEW YORK, May 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, MGM, ALK, MRNA, and MS....
May 27, 2020 08:16 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Pomerantz LLP is investigating claims on behalf of investors of  Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 27, 2020 08:00 am ET
Moderna to Present at Upcoming Investor Conferences
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences:
May 26, 2020 04:30 pm ET
MODERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Moderna, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Moderna, Inc. (NASDAQ: MRNA) on behalf of Moderna stockholders. Our investigation concerns whether Moderna has violated the federal securities laws and/or engaged in other unlawful business practices.
May 26, 2020 08:00 am ET
Moderna to Host Virtual Science Day on June 2, 2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors at 8:00 a.m. ET on Tuesday, June 2.
May 22, 2020 10:50 pm ET
MODERNA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW ORLEANS, May 22, 2020 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mrna/ to learn more....
May 21, 2020 03:31 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Moderna, Inc. (MRNA) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA) investors concerning the Company and its officers’ possible violations of federal securities laws.
May 21, 2020 01:15 pm ET
The Law Offices of Frank R. Cruz Continues Its Investigation on Behalf of Moderna, Inc. Investors (MRNA)
The Law Offices of Frank R. Cruz continues its investigation on behalf of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a...
May 20, 2020 10:50 pm ET
MODERNA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. – MRNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact...
May 20, 2020 04:27 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Moderna, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or “the Company”) (NASDAQ:
May 20, 2020 02:08 pm ET
The Law Offices of Frank R. Cruz Continues Its Investigation on Behalf of Moderna, Inc. Investors (MRNA)
The Law Offices of Frank R. Cruz continues its investigation on behalf of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ:
May 20, 2020 11:00 am ET
Thinking about buying stock in Kitov Pharma, Sorrento Therapeutics, Seanergy Maritime Holdings, Moderna, or MGM Resorts?
NEW YORK, May 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KTOV, SRNE, SHIP, MRNA, and MGM....
May 19, 2020 10:51 pm ET
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Moderna, Inc. Investors (MRNA)
The Law Offices of Frank R. Cruz announces an investigation on behalf of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ:
May 19, 2020 08:06 pm ET
MODERNA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit
May 19, 2020 04:52 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Moderna, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or “the Company”) (NASDAQ:
May 18, 2020 10:32 pm ET
Moderna Announces Pricing of Public Offering of Shares of Common Stock
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. In addition, Moderna has granted the underwriters a 30-day option to purchase up to an additional 2,640,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All
May 18, 2020 04:18 pm ET
Moderna Announces Proposed Public Offering of Shares of Common Stock
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has commenced an underwritten public offering of $1.25 billion in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $187.5 million in shares of common stock in connection with the public offering. All shares of common stock will be offered by Moderna.
May 18, 2020 09:31 am ET
Thinking about trading stocks and options in Moderna, Vir Biotechnology, Scientific Games, American Airlines, or MGM Resorts?
NEW YORK, May 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, VIR, SGMS, AAL, and MGM....
May 18, 2020 07:30 am ET
Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
May 15, 2020 12:53 pm ET
Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House’s Operation Warp Speed Initiative
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Moncef Slaoui has resigned from Moderna’s Board of Directors upon appointment of his new role to oversee the White House’s Operation Warp Speed initiative. Dr. Slaoui joined Moderna’s Board of Directors in 2017.
May 14, 2020 09:31 am ET
Thinking about trading stocks or options in Moderna, Carnival Corp, Minerva Neurosciences, Apple, or Nvidia?
NEW YORK, May 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, CCL, NERV, AAPL, and NVDA....
May 12, 2020 09:31 am ET
Thinking about buying stock in Overstock.com, Moderna, Royal Caribbean Cruises, DexCom, or Walt Disney?
NEW YORK, May 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSTK, MRNA, RCL, DXCM, and DIS....
May 12, 2020 08:00 am ET
Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
May 08, 2020 08:04 am ET
Moderna to Present at Upcoming Investor Conferences
A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.
May 07, 2020 09:31 am ET
Thinking about trading stocks or options in Twilio, Moderna, Walt Disney, Electronic Arts, or Ford?
NEW YORK, May 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TWLO, MRNA, DIS, EA, and F....
May 07, 2020 07:00 am ET
Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results and provided business updates for the first quarter of 2020 and highlighted pipeline progress.
May 01, 2020 09:31 am ET
Thinking about trading stocks or options in Apple, Moderna, Ford, Spirit Airlines, or Netflix?
NEW YORK, May 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, MRNA, F, SAVE, and NFLX....
May 01, 2020 12:50 am ET
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. (SIX: LONN) today announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.
Apr 28, 2020 09:31 am ET
Thinking about trading stocks or options in Arcturus Therapeutics, Laboratory Corp. of America, Bed Bath & Beyond, Moderna, or Zillow?
NEW YORK, April 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARCT, LH, BBBY, MRNA, and Z....
Apr 27, 2020 04:30 pm ET
Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna has received initial feedback from the FDA on the design of the planned Phase 2 study, which is expected to begin in the second quarter of 2020. This study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. Each subject will be assigned to receive placebo, a 50 μg or a 250 μg dose at both vaccinations. The company intends to enroll 600 healthy participants across two cohorts of adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300). Participants will be followed through 12 months after the second v
Apr 23, 2020 08:00 am ET
Moderna to Report First Quarter 2020 Financial Results on Thursday, May 7th, 2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a corporate update.
Apr 21, 2020 09:31 am ET
Thinking about trading options or stock in Beyond Meat, Walt Disney, Lockheed Martin, Moderna, or Tesla?
NEW YORK, April 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BYND, DIS, LMT, MRNA, and TSLA....
Apr 16, 2020 05:55 pm ET
Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (
Apr 15, 2020 09:31 am ET
Thinking about buying stock in Aytu Bioscience, Boeing, Canopy Growth Corp, Moderna, or Rite Aid?
NEW YORK, April 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, BA, CGC, MRNA, and RAD....
Apr 15, 2020 09:00 am ET
Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response
BOSTON, April 15, 2020 /PRNewswire/ -- Ginkgo Bioworks, the organism company, today announced it is contributing its platform infrastructure and expertise to a project with Moderna, Inc. (Nasdaq: MRNA). The collaboration is focused on quickly exploring potential optimizations to Moderna's processes for generating some of the key raw materials used in the manufacturing of its mRNA vaccines, including for mRNA-1273, Moderna's vaccine candidate against COVID-19. Through leveraging Ginkgo's bioengineering know-how and resources, Moderna aims to accelerate its plans to improve the efficiency of t...
Apr 14, 2020 07:00 am ET
Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today is hosting its first Vaccines Day, including presentations highlighting the potential advantages of mRNA vaccines. The Company is also announcing new positive interim Phase 1 data from its Zika vaccine candidate (mRNA-1893). With this data, Moderna’s prophylactic vaccines modality now has seven positive Phase 1 readouts, including a combination vaccine against two viruses (hMPV and PIV3; mRNA-16
Apr 10, 2020 10:53 am ET
Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, to support the health and well-being of the Company’s directors, employees and stockholders, and to comply with the Commonwealth of Massachusetts’ stay at home order, the location of the Company’s 2020 Annual Meeting of Stockholders (including any adjournments or postponements, the
Apr 08, 2020 08:00 am ET
Moderna to Present at 19th Annual Needham Healthcare Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer will participate in the 19th Annual Needham Healthcare Conference on April 14th at 10:40 a.m. ET.
Apr 07, 2020 08:00 am ET
Moderna to Host Virtual Vaccines Day on April 14, 2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its virtual Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 14.
Apr 01, 2020 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, Aytu Bioscience, Inseego, Moderna, or SuperCom?
NEW YORK, April 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, AYTU, INSG, MRNA, and SPCB....
Mar 29, 2020 08:48 pm ET
Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided an update on the impact of the rapidly evolving COVID-19 pandemic on its business operations and clinical program development.
Mar 26, 2020 09:31 am ET
Thinking about buying stock in Chesapeake Energy Corp, Canadian Solar, Moderna, Micron, or Tenet Healthcare?
NEW YORK, March 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHK, CSIQ, MRNA, MU, and THC....
Mar 25, 2020 08:00 am ET
Moderna to Present at MIT Lecture Series
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stéphane Bancel, Chief Executive Officer will participate in the MIT Laboratory for Financial Engineering (LFE) and Golub Center for Finance and Policy (GCFP) Distinguished Lecture Series, “Dealing with Coronavirus: An Industry Perspective” on Wednesday, April 1 from 4:30-6:00 p.m. EDT.
Mar 18, 2020 09:31 am ET
Thinking about buying stock in Cognex, Kroger, Moderna, Nio, or Vaxart?
NEW YORK, March 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGNX, KR, MRNA, NIO, and VXRT....
Mar 16, 2020 12:42 pm ET
Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). This Phase 1 study is being conducted by the National Institutes of Health (NIH) under its own Investigational New Drug (IND) application.
Mar 16, 2020 09:31 am ET
Thinking about buying stock in Ford, Moderna, Progressive, AT&T, or Visa?
NEW YORK, March 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, MRNA, PGR, T, and V....
Mar 03, 2020 04:01 pm ET
Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that enrollment is complete for all three dose cohorts of the Phase 2 dose-confirmation study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647). mRNA-1647, the first mRNA vaccine for an infectious disease to enter a Phase 2 study, is a wholly owned program in Moderna’s prophylactic vaccines portfolio.
Mar 02, 2020 07:37 pm ET
Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced updated plans for its Manufacturing & Digital Day event as a precautionary measure related to travel amid the evolving novel coronavirus situation. The in-person component of the event will no longer be held; the Company will continue with the planned webcast of the program.
Feb 26, 2020 04:30 pm ET
Moderna to Host Manufacturing & Digital Day on March 4, 2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a Manufacturing & Digital Day for analysts and investors at 1:00 p.m. ET on Wednesday, March 4 at the Company’s manufacturing facility in Norwood, Massachusetts.
Feb 26, 2020 07:00 am ET
Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided business updates and reported financial results for the fourth quarter and full year of 2019 and highlighted pipeline progress.
Feb 24, 2020 06:04 pm ET
Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients today announced that it has released the first batch of mRNA-1273, the Company’s vaccine against the novel coronavirus, for human use. Vials of mRNA-1273 have been shipped to the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) to be used in the planned Phase 1 study in the U.S.
Feb 24, 2020 08:00 am ET
Moderna to Present at Upcoming Investor Conferences
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:
Feb 12, 2020 04:30 pm ET
Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2020 to report its fourth quarter and full year 2019 financial results, and provide a corporate update.
Feb 11, 2020 10:12 pm ET
Moderna Announces Pricing of Public Offering of Shares of Common Stock
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of an underwritten public offering of 26,315,790 shares of common stock at a public offering price of $19.00 per share, before underwriting discounts and commissions. In addition, Moderna has granted the underwriters a 30-day option to purchase up to an additional 3,947,368 shares of common stock at the public offering price, less underwriting discounts and commissions. All
Feb 10, 2020 05:11 pm ET
Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Developm
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020. The Company also announced three new vaccine development candidates, which support the Company’s strategy, announced January 12, to accelerate new development candidates in its core modalities, prophylactic vaccines a
Feb 10, 2020 05:10 pm ET
Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the first patient has been enrolled in the Phase 1/2 study evaluating the safety and tolerability of escalating doses of mRNA-3704 administered via intravenous infusion in patients with isolated methylmalonic acidemia (MMA) due to MUT deficiency. This is Moderna’s first rare disease program to begin clinical trial enrollment. The patient has entered an observational period prior to tre
Feb 10, 2020 04:13 pm ET
Moderna Announces Proposed Public Offering of Shares of Common Stock
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has commenced an underwritten public offering of $500 million in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares of common stock in connection with the public offering. All shares of common stock will be offered by Moderna.
Feb 03, 2020 08:00 am ET
Sandra Horning, M.D. To Join Moderna’s Board of Directors
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Sandra Horning, M.D., FACP, FASCO, has been nominated to join its Board of Directors effective as of April 29, 2020, the date of the Company’s annual meeting of stockholders. Dr. Horning has been nominated as a Class II Director and will serve as a member of the Product Development Committee of the Board. Dr. Horning is an academic and industry veteran, most recently serving as Ch
Jan 30, 2020 08:00 am ET
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Melanie Ivarsson, Ph.D., M.B.A., will join the company as its Chief Development Officer. Dr. Ivarsson comes to Moderna from Takeda Pharmaceuticals (NYSE: TAK) where she was Vice President, Head of Global Clinical Operations. Dr. Ivarsson will report to Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna.
Jan 23, 2020 09:15 am ET
Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and the Coalition for Epidemic Preparedness Innovations (CEPI), today announced a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV).
Jan 12, 2020 02:00 pm ET
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has entered a new autoimmune therapeutic area. Building on the clinical validation of systemic delivery of mRNA provided by data from its antibody against the chikungunya virus (mRNA-1944) program, this new therapeutic area will include autoimmune and inflammatory diseases. The Company also announced that it will expand its pipeline of innovative vaccines in the near term, foll
Jan 09, 2020 04:01 pm ET
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive seven-month interim safety and immunogenicity data after the third and final vaccination in the Phase 1 study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647). The findings build on the previously reported three-month interim analysis, after two vaccinations,
Jan 06, 2020 08:30 am ET
Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 38th annual J.P. Morgan Healthcare Conference.
Dec 11, 2019 08:00 am ET
Moderna Announces Key 2020 Investor and Analyst Events
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key 2020 investor and analyst event schedule, including Manufacturing & Digital Day, Vaccines Day, Science Day and R&D Day.
Dec 10, 2019 08:00 am ET
François Nader, M.D., Joins Moderna’s Board of Directors
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that François Nader, M.D., M.B.A. has joined its Board of Directors. Dr. Nader is an experienced biopharmaceutical executive and director with broad expertise across development, regulatory affairs and commercial at NPS Pharmaceuticals (acquired by Shire Plc, now part of Takeda (NYSE: TAK)), as well as Aventis-Pharma and the Pasteur Vaccines division of Rhone-Poulenc, now both p
Nov 26, 2019 08:00 am ET
Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York City on December 3rd at 9:00 a.m. ET.
Nov 06, 2019 07:00 am ET
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided business updates and reported financial results for the third quarter of 2019.
Nov 05, 2019 08:00 am ET
Moderna to Present at Credit Suisse 28th Annual Healthcare Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer, will participate in the Credit Suisse 28th Annual Healthcare Conference in Scottsdale, Arizona on November 13th at 9:45 a.m. ET.
Oct 24, 2019 02:21 pm ET
Moderna Named Top Employer by Science for Fifth Consecutive Year
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced it has been named one of the global biopharmaceutical industry’s top employers in
Oct 22, 2019 04:15 pm ET
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia (PA). The Company
Oct 22, 2019 08:00 am ET
Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2019 to report its third quarter 2019 financial results and provide a corporate update.
Oct 02, 2019 07:00 am ET
Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced data presentations regarding two of its wholly owned prophylactic mRNA vaccines at IDWeek in Washington, D.C. The presentations include interim Phase 1 data from its combination vaccine against the respiratory viruses human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3) (mRNA-1653) and preclinical data from its Zika vaccine (mRNA-1893).
Sep 30, 2019 08:00 am ET
Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the U.S. Food and Drug Administration (FDA) has completed their review of the Investigational New Drug (IND) application for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia (PA) and allowed it to proceed to clinic.
Sep 26, 2019 08:00 am ET
Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University
Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a multi-year research collaboration with Harvard University with the goal of identifying and developing novel therapeutic approaches that could improve the lives of patients with immunological diseases. Additional funding from Moderna to Harvard Medical School (HMS) will establish an initiative at HMS called the Alliance for RNA Therapies for the Modulation of the Immune System (ARTiMI
Sep 25, 2019 08:00 am ET
Moderna to Present at Upcoming Investor Conferences
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:
Sep 12, 2019 06:31 am ET
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. mRNA-1944 encodes for an antibody (CHKV-24) with activity against chikungunya virus. At all three dose levels, the administration of mRNA-1944 led to detectable levels of CHKV-24 antibody in all participants, r
Sep 12, 2019 06:30 am ET
Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647). mRNA-1647 is a wholly owned program in Moderna’s prophylactic vaccine portfolio.
Sep 04, 2019 08:00 am ET
Moderna Appoints Tracey Franklin as Chief Human Resources Officer
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tracey Franklin has been appointed Chief Human Resources Officer. She will serve on Moderna’s Executive Committee, reporting to Chief Executive Officer Stéphane Bancel.
Aug 29, 2019 08:00 am ET
Moderna to Host R&D Day on September 12, 2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its third annual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 12 at the JW Marriott Essex House in New York City.
Aug 27, 2019 08:00 am ET
Moderna to Present at Upcoming Investor Conferences
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:
Aug 19, 2019 04:01 pm ET
Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults.
Aug 07, 2019 07:00 am ET
Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results for the second quarter of 2019 and provided business updates.
Jul 24, 2019 08:00 am ET
Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 7, 2019 to report its second quarter 2019 financial results and provide a corporate update.
Jul 10, 2019 08:00 am ET
Moderna to Present at ROTH RNA Revolution Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer will participate in the ROTH RNA Revolution Conference on July 17, 2019.
Jun 18, 2019 08:00 am ET
Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Pamela Cohen, M.D., Head, Clinical Oncology Development, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 3:20 p.m. ET.
Jun 07, 2019 08:00 am ET
Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019 at 2:00 p.m. PT (5:00 p.m. ET).
Jun 01, 2019 09:00 am ET
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting
Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors. The data showed that the Company’s mRNA personalized cancer vaccine (PCV) mRNA-4157, given alone or in combination with Merck’s pembrolizumab (KEYTRUDA®), was well-tolerated at all doses tested
May 17, 2019 02:01 pm ET
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo. These data supported the initiation of a Phase 1 program of mRNA-1944 against ch
May 10, 2019 09:00 am ET
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of results from two Phase 1 clinical studies showing that mRNA vaccines against H10N8 and H7N9 influenza viruses were well-tolerated and elicited robust immune responses. The results support the potential of mRNA-based vaccines to quickly and effectively address pandemic influenza strains.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.